Corey T McMillan1, Jenny Russ1, Elisabeth M Wood1, David J Irwin1, Murray Grossman1, Leo McCluskey1, Lauren Elman1, Vivanna Van Deerlin1, Edward B Lee2. 1. From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology & Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine & Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia. 2. From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology & Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine & Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia. edward.lee@uphs.upenn.edu mcmillac@upenn.edu.
Abstract
OBJECTIVE: To use in vivo neuroimaging and postmortem neuropathologic analysis in C9orf72 repeat expansion patients to investigate the hypothesis that C9orf72 promoter hypermethylation is neuroprotective and regionally selective. METHODS: Twenty patients with a C9orf72 repeat expansion participating in a high-resolution MRI scan and a clinical examination and a subset of patients (n = 11) were followed longitudinally with these measures. Gray matter (GM) density was related to C9orf72 promoter hypermethylation using permutation-based testing. Regional neuronal loss was measured in an independent autopsy series (n = 35) of C9orf72 repeat expansion patients. RESULTS: GM analysis revealed that hippocampus, frontal cortex, and thalamus are associated with hypermethylation and thus appear to be relatively protected from mutant C9orf72. Neuropathologic analysis demonstrated an association between reduced neuronal loss and hypermethylation in hippocampus and frontal cortex. Longitudinal neuroimaging revealed that hypermethylation is associated with reduced longitudinal decline in GM regions protected by hypermethylation and longitudinal neuropsychological assessment demonstrated that longitudinal decline in verbal recall is protected by hypermethylation. CONCLUSIONS: These cross-sectional and longitudinal neuroimaging studies, along with neuropathologic validation studies, provide converging evidence for neuroprotective properties of C9orf72 promoter hypermethylation. These findings converge with prior postmortem studies suggesting that C9orf72 promoter hypermethylation may be a neuroprotective target for drug discovery.
OBJECTIVE: To use in vivo neuroimaging and postmortem neuropathologic analysis in C9orf72 repeat expansion patients to investigate the hypothesis that C9orf72 promoter hypermethylation is neuroprotective and regionally selective. METHODS: Twenty patients with a C9orf72 repeat expansion participating in a high-resolution MRI scan and a clinical examination and a subset of patients (n = 11) were followed longitudinally with these measures. Gray matter (GM) density was related to C9orf72 promoter hypermethylation using permutation-based testing. Regional neuronal loss was measured in an independent autopsy series (n = 35) of C9orf72 repeat expansion patients. RESULTS: GM analysis revealed that hippocampus, frontal cortex, and thalamus are associated with hypermethylation and thus appear to be relatively protected from mutant C9orf72. Neuropathologic analysis demonstrated an association between reduced neuronal loss and hypermethylation in hippocampus and frontal cortex. Longitudinal neuroimaging revealed that hypermethylation is associated with reduced longitudinal decline in GM regions protected by hypermethylation and longitudinal neuropsychological assessment demonstrated that longitudinal decline in verbal recall is protected by hypermethylation. CONCLUSIONS: These cross-sectional and longitudinal neuroimaging studies, along with neuropathologic validation studies, provide converging evidence for neuroprotective properties of C9orf72 promoter hypermethylation. These findings converge with prior postmortem studies suggesting that C9orf72 promoter hypermethylation may be a neuroprotective target for drug discovery.
Authors: Johannes Brettschneider; Vivianna M Van Deerlin; John L Robinson; Linda Kwong; Edward B Lee; Yousuf O Ali; Nathaniel Safren; Mervyn J Monteiro; Jon B Toledo; Lauren Elman; Leo McCluskey; David J Irwin; Murray Grossman; Laura Molina-Porcel; Virginia M-Y Lee; John Q Trojanowski Journal: Acta Neuropathol Date: 2012-03-18 Impact factor: 17.088
Authors: Adam L Boxer; Ian R Mackenzie; Bradley F Boeve; Matthew Baker; William W Seeley; Richard Crook; Howard Feldman; Ging-Yuek R Hsiung; Nicola Rutherford; Victor Laluz; Jennifer Whitwell; Dean Foti; Eric McDade; Jennifer Molano; Anna Karydas; Aleksandra Wojtas; Jill Goldman; Jacob Mirsky; Pheth Sengdy; Stephen Dearmond; Bruce L Miller; Rosa Rademakers Journal: J Neurol Neurosurg Psychiatry Date: 2010-06-20 Impact factor: 10.154
Authors: Ian R Mackenzie; Thomas Arzberger; Elisabeth Kremmer; Dirk Troost; Stefan Lorenzl; Kohji Mori; Shih-Ming Weng; Christian Haass; Hans A Kretzschmar; Dieter Edbauer; Manuela Neumann Journal: Acta Neuropathol Date: 2013-10-06 Impact factor: 17.088
Authors: Adam L Boxer; Michael Gold; Edward Huey; William T Hu; Howard Rosen; Joel Kramer; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; George Jackson; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven S Khachaturian; Margaret Sutherland; Susan Abushakra; Joseph Lewcock; Robert Farese; Robert O Kenet; Frank Laferla; Steve Perrin; Steve Whitaker; Lawrence Honig; Marsel M Mesulam; Brad Boeve; Murray Grossman; Bruce L Miller; Jeffrey L Cummings Journal: Alzheimers Dement Date: 2012-10-10 Impact factor: 21.566
Authors: Michael J Strong; Gloria M Grace; Morris Freedman; Cathy Lomen-Hoerth; Susan Woolley; Laura H Goldstein; Jennifer Murphy; Christen Shoesmith; Jeffery Rosenfeld; P Nigel Leigh; Lucie Bruijn; Paul Ince; Denise Figlewicz Journal: Amyotroph Lateral Scler Date: 2009-06
Authors: Jennifer L Whitwell; Stephen D Weigand; Bradley F Boeve; Matthew L Senjem; Jeffrey L Gunter; Mariely DeJesus-Hernandez; Nicola J Rutherford; Matthew Baker; David S Knopman; Zbigniew K Wszolek; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Rosa Rademakers; Clifford R Jack; Keith A Josephs Journal: Brain Date: 2012-03 Impact factor: 13.501
Authors: Cyril Pottier; Kevin F Bieniek; NiCole Finch; Maartje van de Vorst; Matt Baker; Ralph Perkersen; Patricia Brown; Thomas Ravenscroft; Marka van Blitterswijk; Alexandra M Nicholson; Michael DeTure; David S Knopman; Keith A Josephs; Joseph E Parisi; Ronald C Petersen; Kevin B Boylan; Bradley F Boeve; Neill R Graff-Radford; Joris A Veltman; Christian Gilissen; Melissa E Murray; Dennis W Dickson; Rosa Rademakers Journal: Acta Neuropathol Date: 2015-05-06 Impact factor: 17.088
Authors: Christopher P Cali; Maribel Patino; Yee Kit Tai; Wan Yun Ho; Catriona A McLean; Christopher M Morris; William W Seeley; Bruce L Miller; Carles Gaig; Jean Paul G Vonsattel; Charles L White; Sigrun Roeber; Hans Kretzschmar; Juan C Troncoso; Claire Troakes; Marla Gearing; Bernardino Ghetti; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Kin Y Mok; Helen Ling; Dennis W Dickson; Gerard D Schellenberg; Shuo-Chien Ling; Edward B Lee Journal: Acta Neuropathol Date: 2019-07-20 Impact factor: 17.088
Authors: Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede Journal: Brain Imaging Behav Date: 2021-01-05 Impact factor: 3.978
Authors: Rustam Esanov; Kinsley C Belle; Marka van Blitterswijk; Veronique V Belzil; Rosa Rademakers; Dennis W Dickson; Leonard Petrucelli; Kevin B Boylan; Derek M Dykxhoorn; Joanne Wuu; Michael Benatar; Claes Wahlestedt; Zane Zeier Journal: Exp Neurol Date: 2015-12-31 Impact factor: 5.330